
(teh nek’ ti plaze)
TNKase
PREGNANCY CATEGORY C
Drug class
Thrombolytic enzyme
Therapeutic Actions
Enzyme that converts plasminogen to the enzyme plasmin (fibrinolysin), which degrades fibrin clots; lyses thrombi and emboli; is most active at the site of the clot and causes little systemic fibrinolysis.
Indications
Reduction of mortality associated with acute MI
Contraindications and Cautions
Contraindicated with allergy to tenecteplase; active internal bleeding; history of stroke; intracranial or intraspinal surgery or trauma (within 2 mo); intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diathesis; severe uncontrolled hypertension.
Use cautiously with recent major surgery, previous puncture of noncompressible vessels, cerebrovascular disease, recent GI or GU bleeding, recent trauma, hypertension, high likelihood of left heart thrombus, acute pericarditis, subacute bacterial endocarditis, hemostatic defects (including those secondary to severe hepatic or renal disease), severe hepatic impairment, pregnancy, diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions, septic thrombophlebitis or occluded AV cannula at seriously infected site, advanced age, patients currently receiving oral anticoagulants, recent use of GP IIb/IIIa inhibitors,
any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location.
Available Forms
Powder for injection—50 mg
Dosages
Adults

Less than 60 kg: 30 mg IV.
60–69 kg: 35 mg IV.
70–79 kg: 40 mg IV.
80–89 kg: 45 mg IV.
90 kg or more: 50 mg IV.
Pediatric patients
Safety and efficacy not established.

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

